At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 16, 2026 at 08:00 ET
ALX Oncology reported Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13, a miss. Cash runway extended to first half 2028. Key catalysts: ALX2004 Phase 1 safety/efficacy data expected December 2026, and ASPEN-09-Breast topline data from 120 patients expected in 2H 2027.
- Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13 (miss).
- Cash, cash equivalents and investments of $147.2M, sufficient to fund operations through first half of 2028.
- R&D expenses of $17.5M, essentially flat YoY.
- ALX2004 Phase 1 dose-escalation safety and early efficacy data expected December 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access